From bacteria to antineoplastic: Epothilones a successful history

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 7, 2013, Pages 1057-1068

  Kaiser, Samuel ^a   Müller, Joseane John ^a   Fröehlich, Pedro Eduardo ^a   Gnoatto, Simone Cristina Baggio ^a   Bergold, Ana Maria ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Anticancer agents; Chemotherapy; Ixabepilone; Patupilone; Sagopilone; Semi syntetic analogs; Structure activity relationship

Indexed keywords

21 AMINOEPOTHILONE B; 9, 10 DIDEHYDROEPOTHILONE D; CAPECITABINE; DOXORUBICIN; EPIRUBICIN; EPOTHILONE B; EPOTHILONE D; EPOTHILONE DERIVATIVE; IXABEPILONE; SAGOPILONE; UNCLASSIFIED DRUG;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; COLORECTAL CANCER; CYTOTOXICITY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; GLIOBLASTOMA; HUMAN; HYPERSENSITIVITY; KIDNEY CANCER; KIDNEY METASTASIS; LUNG CANCER; METASTATIC MELANOMA; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SENSORY NEUROPATHY; STOMACH CANCER; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; BACTERIA; BENZOTHIAZOLES; EPOTHILONES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84882782399     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/18715206113139990133     Document Type: Article

References (140)

1. World Health Organization. International Agency for Research on Cancer: THE GLOBOCAN PROJECT. http://globocan.iarc.fr (Accessed October 31, 2012).
2. Sankaranarayanan, R.; Swaminathan, R.; Brenner, H.; Chen, K.; Chia, K.; Chen, J.; Law, S.; Ahn, Y.; Xiang, Y.; Yeole, B. Cancer survival in Africa, Asia, and Central America: a population-based study. The Lancet Oncology, 2010, 11 (2), 165-173.
3. Mealey, B.L.; Semba, S.E.; Hallmon, W.W. Dentistry and the cancer patient: part 1-oral manifestantions and complications of chemotherapy; Janesburg: Compendium, 1994.
4. Sonis, S.T. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol., 1998, 34(1), 39-43.
5. Souza, M.V.N. New natural products able to act on the stabilization of microtubules, an important target against cancer. Quim. Nova, 2004, 27(2), 308-312.
6. Almeida, V.L.; Leitão, A.; Reina, L.C.B.; Montanari, C.A.; Donnici, C.L.; Lopes, M.T.P. Cancer and cell cicle-specific and cell cicle nonspecific anticancer DNA-interactive agents: an introduction. Quim. Nova, 2005, 28(1), 118-129.
7. Hamel, E. Antimitotic natural products and their interactions with tubulin. Med. Res. Rev., 1996, 16(2), 207-231.
8. Kuppens, I.E.L.M.; Dansin, E.; Boot, H.; Feger, C.; Assadourian, S.; Bonneterre, M-E, Beijnen, J.H.; Schellens, J.H.M.; Bonneterre, J. Dose-Finding Phase I Clinical And Pharmacokinetic Study Of Orally Administered Irinotecan In Patients With Advanced Solid Tumors. Clin. Cancer Res., 2006, 12(12), 3774-3781.
9. Rowinsky, E.K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med., 1997, 48, 353-374.
10. Bollag, D.M.; McQueney, P.A.; Zhu, J.; Hensens, O.; Koupal, L.; Liesch, J.; Goetz, M.; Lazarides, E.; Woods, C.M. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res., 1995, 55(11), 2325-2333.
11. Kowalski, R.J.; Giannakakou, P.; Hamel, E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol®). J. Biol. Chem., 1997, 272(4), 2534-2541.
12. Wolff, A.; Technau, A.; Brandner, G. Ephotilone A induces apoptosis in neuroblastoma cells with multiple mechanisms of drug resistance. Int. J. Oncol., 1997, 11(1), 123-126.
13. Gerth, K.; Bedorf, N.; Höfle, G.; Irschik, H.; Reichenbach, H. Epothilons A and B: Antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria)-Production, physicochemical and biological properties. J. Antibiot., 1996, 49(6), 560-563.
14. Nicolaou, K.C.; Roschangar, F.; Vourloumis, D. Chemical Biology of Epothilones. Angew. Chem., Int. Ed., 1998, 37(15), 2014-2045.
15. U.S. Food and Drug Administration. http://www.fda.gov (Accessed October 29, 2012).
16. Höfle, G.; Bedorf, N.; Gerth, K.; Reichenbach, H. (GBF). DE-B 4138042. Chem. Abstr., 1993, 120, 52841.
17. Höfle, G.; Bedorf, N.; Steinmetz, H.; Schomburg, D.; Gerth, K.; Reichenbach, H. Epothilone A and B-Novel 16-Membered Macrolides with Cytotoxic Activity: Isolation, Crystal Structure, and Conformation in Solution. Angew. Chem., Int. Ed., 1996, 35(13-14), 1567-1569.
18. Höfle, G.; Bedorf, N.; Gerth, K.; Reichenbach, H. (GBF). DE-B 4211055. Chem. Abstr. 1993, 119, 180598.
19. Bode, C.J.; Gupta, M. L.; Reiff, E.A.; Suprenant, K.A.; Georg, G.I.; Himes, R.H. Epothilone and Paclitaxel: Unexpected Differences in Promoting the Assembly and Stabilization of Yeast Microtubules. Biochemistry, 2002, 41(12), 3870-3874.
20. Nettles, J.H.; Li, H.; Cornett, B.; Krahn, J.M.; Snyder, J.P.; Downing, K.H. The Binding Mode of Epothilone A on α,ß-Tubulin by Electron Crystallography. Science, 2004, 305, 866-869.
21. Heinz, D. W.; Schubert, W-D.; Höfle, G. Much Anticipated-The Bioactive Conformation of Epothilone and Its Binding to Tubulin. Angew. Chem., Int. Ed., 2005, 44(9), 1298-1301.
22. Giannakakou, P.; Sackett, D.L.; Kang, Y.K.; Zhan, Z.; Buters, J.T.; Fojo, T.; Poruchynsky, M.S. Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization. J. Biol. Chem., 1997, 272(27), 17118-17125.
23. Winkler, J.; Axelson, P.H. A model for the taxol (paclitaxel)/ epothilone pharmacophore. Bioorg. Med. Chem. Lett., 1996, 6(24), 2963-2966.
24. Reese, M.; Sanchez-Pedregal, V.M.; Kibicek, K.; Meiler, J.; Blommers, M. J.J.; Griesinger, C.; Carlomagno, T. Structural Basis of the Activity of the Microtubule-Stabilizing Agent Epothilone_A Studied by NMR Spectroscopy in Solution. Angew. Chem., Int. Ed., 2007, 46(11), 1864-1868.
25. Manetti, F.; Forli S.; Maccari, L.; Corelli, F.; Botta, M. 3D QSAR studies of the interaction between β -tubulin and microtubule stabilizing antimitotic agents (MSAA). A combined pharmacophore generation and pseudoreceptor modeling approach applied to taxanes and epothilones. Il Farmaco, 2003, 58(5), 357-361.
26. Forli, S.; Manetti, F.; Altmann, K. H.; Botta, M. Evaluation of Novel Epothilone Analogs by means of a Common Pharmacophore and a QSAR Pseudoreceptor Model for Taxanes and Epothilones. ChemMedChem., 2010, 5(1), 35-40.
27. Rivkin, A.; Yoshimura, F.; Fumihiko, G.; Gabarda, A.E.; Cho, Y.S.; Chou, T.C.; Dong, H.; Danishefsky, S.J.; Discovery of (E)-9,10-Dehydroepothilones through Chemical Synthesis:On the Emergence of 26-Trifluoro-(E)-9,10-dehydro-12,13-desoxyepothilone B as a Promising Anticancer Drug Candidate. J. Am. Chem. Soc., 2004, 126(35), 10913-10922.
28. Nicolaou, K.C.; Winssinger, N.; Pastor, J.; Ninkovic, S.; Sarabia, F.; He, Y.; Vourloumis, D.; Yang, Z.; Li, T.; Giannakakou, P.; Hamel, E. Synthesis of epothilones A and B in solid and solution phase. Nature, 1997, 387, 268-272.
29. Chou, T-C.; Zhang, X-G.; Balog, A.; Su, D.; Meng, D.F.; Savin, K.; Bertino, J.R.; Danishefsky, S.J. Desoxyepothilone B: An efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc. Natl. Acad. Sci. U.S.A., 1998, 95(16), 9642-9647.
30. Chou, T-C.; Zhang, X-G.; Harris, C.R.; Kuduk, S.D.; Balog, A.; Savin, K.A.; Bertino, J.R.; Danishefky, S.J. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc. Natl. Acad. Sci. U.S.A., 1998, 95(26), 15798-15802.
31. Chou, T-C.; O'Connor, O. A.; Tong, W. P.; Guan, Y.; Zhang, Z-G.; Stachel, S. J.; Lee, C.; Danishefsky, S. J. The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: Curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Proc. Natl. Acad. Sci. U.S.A., 2001, 98(14), 8113-8118.
32. Altmann, K-H.; Bold, G.; Caravatti, G.; Denni, D.; Flörsheimer, A.; Schmidt, A.; Rihsc, G.; Wartmannb, M. The total synthesis and biological assessment of trans-epothilone A. Helv. Chim. Acta., 2002, 85(11), 4086-4110.
33. Nicolaou, K.C.; Vourloumis, D.; Li, T.; Pastor, J.; Winssinger, N.; Je, T.; Ninkovic, S.; Sarabia, F.; Vallberg, H.; Roschangar, F.; King, P.N.; Finlay, M.R. V.; Giannakakou, P.; Verdier-Pinard, P.; Hamel, E. Designed Epothilones: Combinatorial Synthesis, Tubulin Assembly Properties, and Cytotoxic Action against Taxol-Resistant Tumor Cells. Angew. Chem., Int. Ed., 1997, 36(19), 2097-2103.
34. Nicolaou, K.C.; Ninkovic, S.; Finlay, M.R.V.; Sarabia, F.; Li, T. Total synthesis of 26-hydroxyepothilone B and related analogs. Chem. Commun., 1997, (24), 2343-2344.
35. Newman, R.A.; Yang, J.; Raymond, M.; Finlay, V.; Cabral, F.; Vourloumis, D.; Stephens, L.C.; Troncoso, P.; Wu, X.; Logothetis, C.J.; Nicolaou, K.C.; Navone N.M. Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts. Cancer Chemother. Pharmacol., 2001, 48(4), 319-326.
36. Nicolaou, K.C.; Scarpelli, R.; Bollbuck, B.; Werschkun, B.; Pereira, M.M.A.; Wartmann, M.; Altmann, K.H.; Zaharevitz, D.; Gussio, R.; Giannakakou, P. Chemical synthesis and biological properties of pyridine epothilones. Chem. Biol., 2000, 7(8), 593-599.
37. Borzilleri, R.M.; Zheng, X.; Schmidt, R.J.; Johnson, J.A.; Kim, S.H.; DiMarco, J.D.; Fairchild, C.R.; Gougoutas, J.Z.; Lee, F.Y.F. A Novel Application of a Pd(0)-Catalyzed Nucleophilic Substitution Reaction to the Regio-and Stereoselective Synthesis of Lactam Analogs of the Epothilone Natural Products. J. Am. Chem. Soc., 2000, 122(37), 8890-8897.
38. Lee, F.Y.; Borzilleri, R.; Fairchild, C.R.; Kim, S.H.; Long, B.H.; Suarez, C. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res., 2001, 7(5), 1429-1437.
39. Nicolaou, K.C.; Ritzen, A.; Namoto, K.; Ruben, M.B.; Diaz, F.; Andreu, J.M.; Wartmann, M.; Altmann, K.H.; O'Brate, A.; Giannakakou, P. Chemical synthesis and biological evaluation of novel epothilone B and trans-12, 13-cyclopropyl epothilone B analogs. Tetrahedron, 2002, 58(32), 6413-6432.
40. Höfle, G.; Glaser, N.; Leibold, T.; Karama, U.; Sasse, F.; Steinmetz, H. Semisynthesis and degradation of the tubulin inhibitors epothilone and tubulysin. Pure Appl. Chem., 2003, 75(2-3), 167-178.
41. Nicolaou, K.C.; Vallberg, H.; King, N.P.; Roschangar, F.; He, Y.; Vourloumis, D.; Nicolaou, C.G. Total Synthesis of Oxazole-and Cyclopropane-Containing Epothilone A Analogs by the Olefin Metathesis Approach. Chem. Eur. J., 1997, 3(12), 1957-1970.
42. Nicolaou, K.C.; He, Y.; Roschangar, F.; King, N.P.; Vourloumis, D.; Li T. Total Synthesis of Epothilone E and Analogs with Modified Side Chains through the Stille Coupling Reaction. Angew. Chem., Int. Ed., 1998, 37(1-2), 84-87.
43. Borzilleri, R.M.; Vite, G.D. Epothilones: new tubulin polymerization agents in preclinical and clinical development. Drugs Future, 2002, 27(12), 1149-1163.
44. Lee, C.B.; Chou T.C.; Zhang, X.G.; Wang, Z.G.; Kuduk, S.D.; Chappell M.D.; Stachel, S.J.; Danishefsky, S.J. Total synthesis and antitumor activity of 12,13-desoxyepothilone F: An unexpected solvolysis problem at C15, mediated by remote substitution at C21. J. Org. Chem., 2000, 65(20), 6525-6533.
45. Vite, G.; Höfle, G.; Bifano, M. The semisynthesis and preclinical evaluation of BMS-310705, an epothilone analog in clinical development. 223rd ACS National Meeting, Orlando, USA, 2002.
46. Lee, F.Y.; Vite, G.; Höfle, G. The discovery of BMS-310705: A water soluble and chemically stable semi-synthetic epothilone possessing potent parenteral and oral antitumor activity against models of taxane-sensitive and resistant human tumors in vivo. 93rd Annual AACR Meeting, San Francisco, USA, 2002.
47. Abraham, J.; Agrawal, M.; Bakke, S.; Rutt, A.; Edgerly, M.; Balis, F.M.; Widemann, B.; Davis, L.; Damle, B.; Sonnichsen, D.; Lebwohl, D.; Bates, S.; Kotz, H.; Fojo T. Phase I Trial and Pharmacokinetic Study of BMS-247550, an Epothilone B Analog, Administered Intravenously on a Daily Schedule for Five Days. J. Clin. Oncol., 2003, 21(9), 1866-1873.
48. Mani S.; McDaid, H.; Hamilton, A.; Hochster, H.; Cohen, M.B.; Khabelle, D.; Griffin, T.; Lebwohl, D.E.; Liebes, L.; Muggia, F.; Horwitz, S.B. Phase I Clinical and Pharmacokinetic Study of BMS-247550, a Novel Derivative of Epothilone B, in Solid Tumors. Clin. Cancer Res., 2004, 10(4), 1289-1298.
49. Gadgeel, S.M.; Wozniak, A.; Boinpally, R.R.; Wiegand, R.; Heilbrun, L.K.; Jain, V.; Parchment, R.; Colevas, D.; Cohen, M.B.; Lo Russo, P.M. Phase I Clinical Trial of BMS-247550, A Derivative of Epothilone B, Using Accelerated Titration 2B Design. Clin. Cancer Res., 2005, 11(17), 6233-6239.
50. Zhuang, S.H.; Agrawal, M.; Edgerly, M.; Bakke, S.; Kotz, H.; Thambi, P.; Rutt, A.; Balis, F.M.; Bates, S.; Fojo, T. A Phase I Clinical Trial of ixabepilone (BMS-247550), an Epothilone B Analog, Administered Intravenously on a Daily Schedule for 3 Days. Cancer, 2005, 103(9), 1932-1938.
51. Aghajanian, C.; Burris, H.A.; Jones, S.; Spriggs, D.R.; Cohen, M.B.; Peck, R.; Sabbatini, P.; Hensley, M.L.; Greco, F.A.; Dupont, J.; O'Connor, O.A. Phase I Study of the Novel Epothilone Analog Ixabepilone (BMS-247550) in Patients With Advanced Solid Tumors and Lymphomas. J. Clin. Oncol., 2007, 25(9), 1082-1088.
52. Hensley, M.L.; Dizon, D.; Derosa, F.; Venkatraman, E.; Sabbatini, P.; Chi, D.S.; Dupont, J.; Colevas, A.D.; Spriggs, D.; Aghajanian, C. A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. Invest. New Drugs, 2007, 25(4), 335-341.
53. Shimizu, T.; Yamamoto, N.; Yamada, Y.; Fujisaka, Y.; Yamada, K.; Fujiwara, Y.; Takayama, K.; Tokudome, T.; Klimovsky, J.; Tamura, T. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors. Cancer Chemother. Pharmacol., 2008, 61(5), 751-758.
54. Bunnell, C.; Vahdat, L.; Schwartzberg, L.; Gralow, J.; Klimovsky, J.; Poulart, V.; Peck, R.; Thomas, E. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxaneresistant metastatic breast cancer. Clin. Breast Cancer, 2008, 8(3), 234-241.
55. Plummer, R.; Woll, P.; Fyfe, D.; Boddy, A.V.; Griffin, M.; Hewitt, P.; Carmichael, J.; Namouni, F.; Cohen, M.; Verrill, M. A Phase I and Pharmacokinetic Study of Ixabepilone in Combination with Carboplatin in Patients with Advanced Solid Malignancies. Clin. Cancer Res., 2008, 14(24), 8288-8294.
56. Awada, A.; Piccart, M.J.; Jones, S.F.; Peck, R.A.; Gil, T.; Lebwohl, D.; Wu, C.Y.; Burris, H.A. Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy. Cancer Chemother. Pharmacol., 2009, 63(3), 417-425.
57. Widemann, B.C.; Goodspeed, W.; Goodwin, A.; Fojo, T.; Balis, F.M.; Fox, E. Phase I Trial and Pharmacokinetic Study of Ixabepilone Administered Daily for 5 Days in Children and Adolescents With Refractory Solid Tumors. J. Clin. Oncol., 2009, 27(4), 550-556.
58. Rosenberg, J.E.; Ryan, C.J.; Weinberg, V.K.; Smith, D.C.; Hussain, M.; Beer, T.M.; Ryan, C.W.; Mathew, P.; Pagliaro, L.C.; Harzstark, A.L.; Sharib, J.; Small, E.J. Phase I Study of Ixabepilone, Mitoxantrone, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy: A Study of the Department of Defense Prostate Cancer Clinical Trials Consortium. J. Clin. Oncol., 2009, 27(17), 2772-2778.
59. Chuang, E.; Wiener, N.; Christos, P.; Kessler, R.; Cobham, M.; Donovan, D.; Goldberg, G.L.; Caputo, T.; Doyle, A.; Vahdat L.; Sparano, J.A. Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary. Ann. Oncol., 2010, 21(10), 2075-2080.
60. Roché, H.; De Benedictis, E.; Cottura, E.; Govi, S.; Dalenc, F.; Locatelli, A.; Deslandres, M.; Zambetti, M.; Gladieff, L.; Messina, M.; Gianni, L. A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer. Clin. Breast Cancer, 2012, 12(3), 167-174.
61. Kunz, P.L.; He, A.R.; Colevas, A.D.; Pishvaian, M.J.; Hwang, J.J.; Clemens, P.L.; Messina, M.; Kaleta, R.; Abrahao, F.; Sikic, B.I.; Marshall, J.L. Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors. Invest. New Drugs, 2012, 30(6), 2364-2370.
62. Eng, C.; Kindler, H.L.; Nattam, S.; Ansari, R.H.; Kasza, K.; Wade-Oliver, K.; Vokes, E.E. A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann. Oncol., 2004, 15(6), 928-932.
63. Low, J.A.; Wedam, S.B.; Lee, J.J.; Berman, A.W.; Brufsky, A.; Yang, S. X.; Poruchynsky, M.S.; Steinberg, S.M.; Mannan, N.; Fojo, T.; Swain, S.M.; Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Metastatic and Locally Advanced Breast Cancer. J. Clin. Oncol., 2005, 23(12), 2726-2734.
64. Liu, G.; Chen, Y.H.; Dipaola, R.; Carducci, M.; Wilding, G. Phase II trial of weekly ixabepilone in men with metastatic castrateresistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group. Clin. Genitourin. Cancer, 2012, 10(2), 99-105.
65. Okuno, S.; Maples, W.J.; Mahoney, M.R.; Fitch, T.; Stewart, J.; Fracasso, P.M.; Kraut, M.; Ettinger, D.S.; Dawkins, F.; Erlichman, C. Evaluation of Epothilone B Analog in Advanced Soft Tissue Sarcoma: A Phase II Study of the Phase II Consortium. J. Clin. Oncol., 2005, 23(13), 3069-3073.
66. Galsky, M. D.; Small, E. J.; Oh, W. K.; Chen, I.; Smith, D. C.; Colevas, A. D.; Martone, L.; Curley, T.; Delacruz, A.; Scher, H. I.; Kelly, W. K.; Multi-Institutional Randomized Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) with or without Estramustine Phosphate in Patients with Progressive Castrate Metastatic Prostate Cancer. J. Clin. Oncol. 2005, 23, 1439.
67. Rosenberg, J.E.; Galsky, M.D.; Rohs, N.C.; Weinberg, V.K.; Oh, W.K.; Kelly, W.K.; Small, E.J. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: Second-line taxane-based therapy after first-line epothilone-B analog ixahepilone (BMS-247550) therapy. Cancer, 2006, 106(1), 58-62.
68. Ajani, J.A.; Safran, H.; Bokemeyer, C.; Shah, M.A.; Lenz, H.J.; Van Cutsem, E.; Burris, H.A.; Lebwohl, D.; Mullaney, B. A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest. New Drugs, 2006, 24(5), 441-446.
69. Whitehead, R.P.; McCoy, S.; Rivkin, S.E.; Gross, H.M.; Conrad, M.E.; Doolittle, G.C.; Wolff, R.A.; Goodwin, J.W.; Dakhil, S.R.; Abbruzzese, J.L. A Phase II trial of epothilone B analogue BMS-247550 (NSC#710428) ixabepilone, in patients with advanced pancreas cancer: A Southwest Oncology Group study. Invest. New Drugs, 2006, 24(6), 515-520.
70. Denduluri, N.; Lee, J.J.; Walshe, J.; Berman, A.W.; Vatas, U.; Chow, C.K.; Steinberg, S.M.; Cox, M.C.; Low, J.A.; Swain, S.M. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest. New Drugs, 2007, 25(1), 63-67.
71. Posadas, E.M.; Undevia, S.; Manchen, E.; Wade, J.L.; Colevas, A.D.; Karrison, T.; Vokes, E.E.; Stadler, W.M. A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma. Cancer Biol. Ther., 2007, 6(4), 490-493.
72. Perez, E.A.; Lerzo, G.; Pivot, X.; Thomas, E.; Vahdat, L.; Bosserman, L.; Viens, P.; Cai, C.; Mullaney, B.; Peck, R.; Hortobagyi, G.N. Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine. J. Clin. Oncol., 2007, 25(23), 3407-3414.
73. Roché, H.; Yelle, L.; Cognetti, F.; Mauriac, L.; Bunnell, C.; Sparano, J.; Kerbrat, P.; Delord, J-P.; Vahdat, L.; Peck, R.; Lebwohl, D.; Ezzeddine, R.; Curé, H. Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, As First-Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline Chemotherapy. J. Clin. Oncol., 2007, 25(23), 3415-3420.
74. Denduluri, N.; Low, J.A.; Lee, J.J.; Berman, A.W.; Walshe, J.M.; Vatas, U.; Chow, C.K.; Steinberg, S.M.; Yang, S.X.; Swain, S.M. Phase II Trial of Ixabepilone, an Epothilone B Analog, in Patients With Metastatic Breast Cancer Previously Untreated With Taxanes. J. Clin. Oncol., 2007, 25(23), 3421-3427.
75. Vansteenkiste, J.; Lara, P.N. Jr.; Le Chevalier, T.; Breton, J.L.; Bonomi, P.; Sandler, A.B.; Socinski, M.A.; Delbaldo, C.; McHenry, B.; Lebwohl, D.; Peck, R.; Edelman, M.J. Phase II Clinical Trial of the Epothilone B Analog, Ixabepilone, in Patients With Non-Small-Cell Lung Cancer Whose Tumors Have Failed First-Line Platinum-Based Chemotherapy. J. Clin. Oncol. 2007, 25(23), 3448-3455.
76. Thomas, E.; Tabernero, J.; Fornier, M.; Conté, P.; Fumoleau, P.; Lluch, A.; Vahdat, L.T.; Bunnell, C.A.; Burris, H.A.; Viens, P.; Baselga, J.; Rivera, E.; Guarneri, V.; Poulart, V.; Klimovsky, J.; Lebwohl, D.; Martin, M. Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients with Taxane-Resistant Metastatic Breast Cancer. J. Clin. Oncol., 2007, 25(23), 3399-3406.
77. Feldman, D.R.; Kondagunta, G.V.; Ginsberg, M.S.; Ishill, N.; Patil, S.; Cestaro, J.; Obbens, E.; Sheinfeld, J.; Bosl, G.J.; Motzer, R.J. Phase II Trial of ixabepilone in patients with cisplatin-refractory germ cell tumor. Invest. New Drugs, 2007, 25(5), 487-490.
78. Burtness, B.A.; Manola, J.; Axelrod, R.; Argiris, A.; Forastiere, A.A. A randomized phase II study of ixabepilone (BMS-247550) given daily 3 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann. Oncol., 2008, 19(5), 977-983.
79. O'Connor, O.A.; Portlock, C.; Moskowitz, C.; Straus, D.; Hamlin, P.; Stubblefield, M.; Dumetrescu, O.; Colevas, A.D.; Grant, B.; Zelenetz, A. A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma. Br. J. Haematol., 2008, 143(2), 201-209.
80. Baselga, J.; Zambetti, M.; Llombart-Cussac, A.; Manikhas, G.; Kubista, E.; Steger, G.G.; Makhson, A.; Tjulandin, S.; Ludwig, H.; Verrill, M.; Ciruelos, E.; Egyhazi, S.; Xu, L.A.; Zerba, K.E.; Lee, H.; Clark, E.; Galbraith, S. Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer. J. Clin. Oncol., 2009, 27(4), 526-534.
81. Dizon, D.S.; Blessing, J.A.; McMeekin, D.S.; Sharma, S.K.; Disilvestro, P.; Alvarez, R.D. Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-P. J. Clin. Oncol., 2009, 27(19), 3104-3108.
82. De Geest, K.; Blessing, J.A.; Morris, R.T.; Yamada, S.D.; Monk, B.J.; Zweizig, S.L.; Matei, D.; Muller, C.Y.; Richards, W.E. Phase II Clinical Trial of Ixabepilone in Patients With Recurrent or Persistent Platinum-and Taxane-Resistant Ovarian or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study. J. Clin. Oncol., 2010, 28(1), 149-153.
83. Jacobs, S.; Fox, E.; Krailo, M.; Hartley, G.; Navid, F.; Wexler, L.; Blaney, S.M.; Goodwin, A.; Goodspeed, W.; Balis, F.M.; Adamson, P.C.; Widemann, B. C. Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group. Clin. Cancer Res., 2010, 16(2), 750-754.
84. Ott, P.A.; Hamilton, A.; Jones, A.; Haas, N.; Shore, T.; Liddell, S.; Christos, P.J.; Doyle, L.A.; Millward, M.; Muggia, F.M.; Pavlick, A.C. A Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) in Patients with Metastatic Melanoma. PLoS One, 2010, 5(1), e8714.
85. Moulder, S.; Li, H.; Wang, M.; Gradishar, W.J.; Perez, E.A.; Sparano, J.A.; Pins, M.; Yang, X.; Sledge, G.W. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. Breast Cancer Res. Treat., 2010, 119(3), 663-671.
86. Huang, H.; Menefee, M.; Edgerly, M.; Zhuang, S.; Kotz, H.; Poruchynsky, M.; Huff, L.M.; Bates, S.; Fojo, T. A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma. Clin. Cancer Res., 2010, 16(5), 1634-1641.
87. Wang, J.; Fan, Y.; Xu, B. Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment. Cancer Chemother. Pharmacol., 2010, 66(3), 597-603.
88. Harzstark, A.L.; Rosenberg, J.E.; Weinberg, V.K.; Sharib, J.; Ryan, C.J.; Smith, D.C.; Pagliaro, L.C.; Beer, T.M.; Liu, G.; Small, E.J. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the department of defense prostate cancer clinical trials consortium. Cancer, 2011, 117(11), 2419-2425.
89. Kim, Y.H.; Muro, K.; Yasui, H.; Chen, J.S.; Ryu, M.H.; Park, S.H.; Chu, K.M.; Choo, S.P.; Sanchez, T.; Delacruz, C.; Mukhopadhyay, P.; Lainas, I.; Li, C.P. A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy. Cancer Chemother. Pharmacol., 2012, 70(4), 583-590.
90. Spigel, D.R.; Anthony Greco, F.; Waterhouse, D.M.; Shipley, D.L.; Zubkus, J.D.; Bury, M.J.; Webb, C.D.; Hart, L.L.; Gian, V.G.; Infante, J.R.; Burris, H.A.; Hainsworth, J.D. Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer. Lung Cancer, 2012, 78(1), 70-75.
91. Thomas, E.S.; Gomez, H.L.; Li, R.K.; Chung, H.C.; Fein, L.E.; Chan, V.F.; Jassem, J.; Pivot, X.B.; Klimovsky, J.V.; De Mendoza, F.H.; Xu, B.; Campone, M.; Lerzo, G.L.; Peck, R.A.; Mukhopadhyay, P.; Vahdat, L.T.; Roché, H. H. Ixabepilone Plus Capecitabine for Metastatic Breast Câncer Progressing After Anthracycline and Taxane Treatment. J. Clin. Oncol., 2007, 25(33), 5210-5217.
92. Hortobagyi, G.N.; Gomez, H.L.; Li, R.K.; Chung, H.C.; Fein, L.E.; Chan, V.F.; Jassem, J.; Lerzo, G.L.; Pivot, X.B.; De Mendoza F.H.; Xu, B.; Vahdat, L.T.; Peck, R.A.; Mukhopadhyay, P.; Roché, H. H. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res. Treat., 2010, 122(2), 409-418.
93. Sparano, J.A.; Vrdoljak, E.; Rixe, O.; Xu, B.; Manikhas, A.; Medina, C.; Da Costa S.C.; Ro, J.; Rubio, G.; Rondinon, M.; Manga, G.P.; Peck, R.; Poulart, V.; Conte, P. Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. J. Clin. Oncol., 2010, 28(20), 3256-3263.
94. Roché, H.; Conte, P.; Perez, E.A.; Sparano, J.A.; Xu, B.; Jassem, J.; Peck, R.; Kelleher, T.; Hortobagyi, G.N. Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies. Breast Cancer Res. Treat., 2011, 125(3), 755-765.
95. Jassem, J.; Fein, L.; Karwal, M.; Campone, M.; Peck, R.; Poulart, V.; Vahdat, L. Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies. The Breast, 2012, 21(1), 89-94.
96. Rubin, E.H.; Rothermel, J.; Tesfaye, F.; Chen, T.; Hubert, M.; Ho, Y.Y.; Hsu, C.H.; Oza, A.M. Phase I Dose-Finding Study of Weekly Single-Agent Patupilone in Patients With Advanced Solid Tumors. J. Clin. Oncol., 2005, 23(36), 9120-9129.
97. Forster, M.; Kaye, S.; Oza, A.; Sklenar, I.; Johri, A.; Cheung, W.; Zaknoen, S.; Gore, M. A Phase Ib and Pharmacokinetic Trial of Patupilone Combined with Carboplatin in Patients with Advanced Cancer. Clin. Cancer Res., 2007, 13(14), 4178-4184.
98. Schelman, W.; Morgan-Meadows, S.; Bailey, H.; Holen, K.; Thomas, J. P.; Eickhoff, J.; Brandon, H.; Oliver, K.; Alberti, D.; Wilding, G. A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors. Cancer Chemother. Pharmacol., 2008, 62(4), 727-733.
99. Ten Bokkel Huinink, W.W.; Sufliarsky, J.; Smit, W.M.; Spanik, S.; Wagnerova, M.; Hirte, H.W.; Kaye, S.; Johri, A.R.; Oza, A.M. Safety and Efficacy of Patupilone in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer A Phase I, Open-Label, Dose-Escalation Study. J. Clin. Oncol., 2009, 27(19), 3097-3103.
100. Fogh, S.; Machtay, M.; Werner-Wasik, M.; Curran, W.J. Jr.; Bonanni, R.; Axelrod, R.; Andrews, D.; Dicker, A.P. Phase I trial using Patupilone (Epothilone B) and concurrent radiotherapy for central nervous system malignancies. Int. J. Radiat. Oncol. Biol. Phys., 2010, 77(4), 1009-1016.
101. Melichar, B.; Casado, E.; Bridgewater, J.; Bennouna, J.; Campone, M.; Vitek, P.; Delord, J.P.; Cerman, J. Jr.; Salazar, R.; Dvorak, J.; Sguotti, C.; Urban, P.; Viraswami-Appanna, K.; Tan, E.; Tabernero, J. Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial. Br. J.Cancer, 2011, 105(11), 1646-1653.
102. Oehler, C.; Frei, K.; Rushing, E.J.; McSheehy, P.M.; Weber, D.; Allegrini, P.R.; Weniger, D.; Lütolf, U.M.; Knuth, A.; Yonekawa, Y.; Barath, K.; Broggini-Tenzer, A.; Pruschy, M.; Hofer, S. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial. Oncology, 2012, 83(1), 1-9.
103. Larkin, J.M.G.; Kaye, S.B. Potential clinical applications of epothilones: a review of phase II studies. Ann. Oncol., 2007, 18(5), 28-34.
104. Hussain, A.; DiPaola, R.S.; Baron, A.D.; Higano, C.S.; Tchekmedyian, N.S.; Johri, A.R. Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann. Oncol., 2009, 20(3), 492-497.
105. Colombo, N.; Kutarska, E.; Dimopoulos, M.; Bae, D-S; Rzepka-Gorska, I.; Bidzinski, M.; Scambi, G.; Engelholm, S.A.; Joly, F.; Weber, D.; El-Hashimy, M.; Li, J.; Souami, F.; Wing, P.; Engelholm, S.; Bamias, A.; Schwartz, P. Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or-Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer. J. Clin. Oncol., 2012, 20(21), 3841-3847.
106. Fumoleau, P.; Coudert, B.; Isambert, N.; Ferrant, E. Novel tubulintargeting agents: anticancer activity and pharmacologic profile of epothilones and related analogs. Ann. Oncol., 2007, 18(5), 9-15.
107. Sessa, C.; Perotti, A.; Lladò, A.; Cresta, S.; Capri, G.; Voi, M.; Marsoni, S.; Corradino, I.; Gianni, L. Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule. Ann. Oncol., 2007, 18(9), 1548-1553.
108. Arnold, D.; Voigt, W.; Kiewe, P.; Behrmann, C.; Lindemann, S.; Reif, S.; Wiesinger, H.; Giurescu, M.; Thiel, E.; Schmoll, H-J. Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial. Br. J. Cancer., 2009, 101(8), 1241-1247.
109. Schmid, P.; Kiewe, P.; Possinger, K.; Korfel, A.; Lindemann, S.; Giurescu, M.; Reif, S.; Wiesinger, H.; Thiel, E.; Kühnhardt, D. Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors. Ann. Oncol., 2010, 21(3), 633-639.
110. Araki, K.; Kitagawa, K.; Mukai, H.; Mukohara, T.; Kodama, K.; Ando, Y.; Narabayashi, M.; Minami, H.; Mera, K.; Sasaki, Y. First clinical pharmacokinetic dose-escalation study of sagopilone, a novel, fully synthetic epothilone, in Japanese patients with refractory solid tumors. Invest. New Drugs, 2012, 30(6), 2327-2333.
111. McMeekin, S.; Patel, R.; Verschraegen, C.; Celano, P.; Burke, J.; Plaxe, S.; Ghatage, P.; Giurescu, M.; Stredder, C.; Wang, Y.; Schmelter, T. Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer. Br. J. Cancer, 2012, 106(1), 70-76.
112. Morrow, P.K.; Divers, S.; Provencher, L.; Luoh, S.W.; Petrella, T.M.; Giurescu, M.; Schmelter, T.; Wang, Y.; Hortobagyi, G.N.; Vahdat, L.T. Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy. Breast Cancer Res. Treat., 2010, 123(3), 837-842.
113. Freedman, R.A.; Bullitt, E.; Sun, L.; Gelman, R.; Harris, G.; Ligibel, J.A.; Krop, I.E.; Partridge, A.H.; Eisenberg, E.; Winer, E.P.; Lin, N.U. A phase II study of sagopilone (ZK 219477; ZKEPO) in patients with breast cancer and brain metastases. Clin. Breast Cancer, 2011, 11(6), 376-383.
114. Stupp, R.; Tosoni, A.; Bromberg, J.E.C.; Hau, P.; Campone, M.; Gijtenbeek, J.; Frenay, M.; Breimer, L.; Wiesinger, H.; Allgeier, A.; van den Bent, M.J.; Bogdahn, U.; van der Graaf, W.; Yun, H.J.; Gorlia, T.; Lacombe, D.; Brandes, A. A. Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. Ann. Oncol., 2011, 22(9), 2144-2149.
115. DeConti, R.C.; Algazi, A.P.; Andrews, S.; Urbas, P.; Born, O.; Stoeckigt, D.; Floren, L.; Hwang, J.; Weber, J.; Sondak, V.K.; Daud, A.I. Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma. Br. J. Cancer., 2010, 103(10), 1548-1553.
116. Rustin, G.; Reed, N.; Jayson, G.C.; Ledermann, J.A.; Adams, M.; Perren, T.; Poole, C.; Lind, M.; Persic, M.; Essapen, S.; Gore, M.; Calvert, H.; Stredder, C.; Wagner, A.; Giurescu, M.; Kaye S. A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Ann. Oncol., 2011, 22(11), 2411-2416.
117. Beer, T.M.; Smith, D.C.; Hussain, A.; Alonso, M.; Wang, J.; Giurescu, M.; Roth, K.; Wang, Y. Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium. Br. J. Cancer, 2012, 107(5), 808-813.
118. Monk, J.; Calero-Villalona, M.; Dupont, J.; Larkin, J.; Otterson, G.; Spriggs, D.; Hannah, A.L.; Cropp, G.F.; Johnson, R.G.; Hensley, M.L. Phase 1 trial of KOS-862 (epothilone D) in combination with carboplatin (C) in patients with solid tumors. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings, 2005, 23(16S), 2049.
119. Marshall, J.L.; Ramalingam, S.; Hwang, J.J.; Ramanathan, R.; Malik, S.; Egorin, M.; Hannah, A.; Cropp, G.F.; Johnson, R.G.; Belani, C. Phase 1 and pharmacokinetic (PK) study of weekly KOS-862 (epothilone D) combined with gemcitabine (GEM) in patients (pts) with advanced solid tumors. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings, 2005, 23(16S), 2041.
120. Cortes, J.; Climent, M.; Gomez, P.; Ruiz, A.; Calvo, E.; Zhang, X.; Perez, E.S.; Demario, M.; Baselga, J. Phase I trial of weekly combination KOS-862 (epothilone D) and trastuzumab in HER-2 overexpressing malignancies. J. Clin. Oncol., 2006 ASCO Annual Meeting Proceedings, 2006, 24(18S), 2028.
121. Konner, J.; Grisham, R.N.; Park, J.; O'Connor, O.A.; Cropp, G.; Johnson, R.; Hannah, A.L.; Hensley, M.L.; Sabbatini, P.; Miranov, S.; Danishefsky, S.; Hyman, D.; Spriggs, D.R.; Dupont, J.; Aghajanian, C. Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma. Invest. New Drugs, 2012, 30(6), 2294-2302.
122. Monk, J.P.; Villalona-Calero, M.; Larkin, J.; Otterson, G.; Spriggs, D.S.; Hannah, A.L.; Cropp, G.F.; Johnson, R.G.; Hensley, M.L. A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors. Invest. New Drugs, 2012, 34(4), 1676-1683.
123. Overmoyer, B.; Waintraub, S.; Kaufman, P.; Doyle, T.; Moore, H.; Modiano, M.; Kroener, J. Zhang Buzdar, A. Demario, M Phase II trial of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings, 2005, 23(16S), 778.
124. Beer, T.M.; Higano, C.S.; Saleh, M.; Dreicer, R.; Hudes, G.; Picus, J.; Rarick, M.; Fehrenbacher, L.; Hannah, A.L. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest. New Drugs, 2007, 25(6), 565-570.
125. Stopeck, A.; Thomas, E.; Jones, S.; Cohen, J.; Cropp, G.; Zhou, Y.; Feng, L.; Kersey, K.; Hannah, A.L.; Burris, H. Phase I trial of a novel epothilone, KOS-1584, using a weekly dosing schedule. J. Clin. Oncol., 2006 ASCO Annual Meeting Proceedings, 2006, 24(18S), 2041.
126. Stopeck, A.; Moulder, S.; Jones, S.; Cohen, J.; McDowell, M.; Cropp, G.; Zhong, Z.; Wells, S.; Hannah, A.; Burris, H. Phase I trial of KOS-1584 (a novel epothilone) using two weekly dosing schedules. J. Clin. Oncol., 2007 ASCO Annual Meeting Proceedings, 2007, 25(18S), 2571.
127. Lam, E.T.; Goel, S.; Schaaf, L.J.; Cropp, G.F.; Hannah, A.L.; Zhou, Y.; McCracken, B.; Haley, B.I.; Johnson, R.G.; Mani, S.; Villalona-Calero, M.A. Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors. Cancer Chemother. Pharmacol., 2012, 69(2), 523-531.
128. Valero, V.; Vrdoljak, E.; Xu, B.; Thomas, E.; Gómez, H.; Manikhas, A.; Medina, C.; Li, R.K.; Ro, J.; Bosserman, L.; Vahdat, L.; Mukhopadhyay, P.; Opatt, D.; Sparano, J.A. Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline-and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials. Clin. Breast Cancer, 2012, 12(4), 240-246.
129. Vahdat, L.T.; Thomas, E.S.; Roché, H.H.; Hortobagyi, G.N.; Sparano, J.A.; Yelle, L.; Fornier, M.N.; Martín, M.; Bunnell, C.A.; Mukhopadhyay, P.; Peck, R.A.; Perez, E.A. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. Support. Care Cancer, 2012, 20(11), 2661-2668.
130. Valero, V. Managing Ixabepilone Adverse Events With Dose Reduction. Clin. Breast Cancer, 2012, In press.
131. ClinicalTrials.gov. http://www.clinicaltrials.gov (Accessed October 30, 2012).
132. Altmann, K.H. Recent developments in the chemical biology of epothilones. Curr. Pharm. Des., 2005, 11(13), 1595-1613.
133. Klar, U.; Buchmann, B.; Schwede, W.; Skuballa, W.; Hoffmann, J.; Lichtner, R.B. Total synthesis and antitumor activity of ZKEPO: the first fully synthetic epothilone in clinical development. Angew. Chem., Int. Ed., 2006, 118(47), 8110-8116.
134. Kuzniewski, C.N; Gertsch, J.; Wartmann, M.; Altmann, K. Total Synthesis of Hypermodified Epothilone Analogs with Potent in vitro Antitumor Activity. Org. Lett., 2008, 10(6), 1183-1186.
135. Schiess, R.; Gertsch, J.; Schweizer, W.B.; Altmann, K. Stereoselective Synthesis of 12,13-Cyclopropyl-Epothilone B and Side-Chain-Modified Variants. Org. Lett., 2011, 13(6), 1436-1439.
136. Sefkow, M.; Kiffe, M.; Höfle, G. Derivatization of the C12-C13 functional groups of epothilones A, B and C. Bioorg. Med. Chem. Lett., 1998, 8, 3031-3036.
137. Pfeiffer, B.; Hauenstein, K.; Merz, P.; Gertsch, J.; Altmann, K. Synthesis and SAR of C12-C13-oxazoline derivatives of epothilone A. Bioorg. Med. Chem. Lett., 2009, 19, 3760-3763.
138. Duan, X.; Zhang, Y.; Ding, Y.; Lin, J.; Kong, X.; Zhang, Q.; Dong, C.; Luo, G.; Chen, Y. Synthesis of Triazole-Epothilones by Using Cu2O Nanoparticles to Catalyze 1,3-Dipolar Cycloaddition. Eur. J. Org. Chem. 2012, 3, 500-508.
139. Nicolaou, K.C.; Hepworth, D.; King, N.P.; Finlay, M.R.V.; Scarpelli, R.; Perreira, M.M.A.; Bollbuck, B.; Bigot, A.; Werschkun, B.; Winssinger, N. Total Synthesis of 16-Desmethylepothilone B, Epothilone B10, Epothilone F and Related Side Chain Modified Epothilone B Analogs. Chem. Eur. J. 2000, 6(15), 2783-2800.
140. Passarella, D.; Comi, D.; Cappelletti, G.; Cartelli, D.; Gertsch, J.; Quesada, A.Q.; Borlak, J.; Altmann, K. Synthesis and biological evaluation of epothilone A dimeric compounds. Bioorg. Med. Chem., 2009, 17, 7435-7440.